Featured Dataverses

In order to use this feature you must have at least one published or linked dataverse.

Publish Dataverse

Are you sure you want to publish your dataverse? Once you do so it must remain published.

Publish Dataverse

This dataverse cannot be published because the dataverse it is in has not been published.

Delete Dataverse

Are you sure you want to delete your dataverse? You cannot undelete this dataverse.

Advanced Search

1 to 10 of 14 Results
Replication for Week 48 Data for Switching Treatment-Experienced, Integrase Inhibitor-Naïve, Virally Suppressed HIV-1 Infected Adults from Ritonavir boosted Protease Inhibitors to Dolutegravir: An Open-Label Randomized Controlled Trial
Dec 2, 2022 - Revised Week 48 Data
Ombajo, Loice Achieng, 2022, "Replication for Week 48 Data for Switching Treatment-Experienced, Integrase Inhibitor-Naïve, Virally Suppressed HIV-1 Infected Adults from Ritonavir boosted Protease Inhibitors to Dolutegravir: An Open-Label Randomized Controlled Trial", https://doi.org/10.7910/DVN/GIEE3K, Harvard Dataverse, V1, UNF:6:nDxWIz5UO+oMBMqROvb6QA== [fileUNF]
This is week 48 dataset from an open-label, randomized, active-controlled, multi-centre non-inferiority trial conducted by University of Nairobi. The trial enrolled 791 participants ≥ 18 years old from among people receiving outpatient HIV care at four study sites in Kenya. The variables contained in this dataset are; demographics, ARV history, bod...
2SD WK48 Codes_Baseline, Efficacy, Imputation and Lab AEs.do
Dec 2, 2022 - Replication for Week 48 Data for Switching Treatment-Experienced, Integrase Inhibitor-Naïve, Virally Suppressed HIV-1 Infected Adults from Ritonavir boosted Protease Inhibitors to Dolutegravir: An Open-Label Randomized Controlled Trial
Stata Syntax - 41.8 KB - MD5: bb2c5f73d6d31b34255c93364967c039
STATA codes for baseline, efficacy, imputation and lab AEs data analysis
2SD WK48 Data_Baseline and Efficacy.tab
Dec 2, 2022 - Replication for Week 48 Data for Switching Treatment-Experienced, Integrase Inhibitor-Naïve, Virally Suppressed HIV-1 Infected Adults from Ritonavir boosted Protease Inhibitors to Dolutegravir: An Open-Label Randomized Controlled Trial
Tabular Data - 478.5 KB - 95 Variables, 791 Observations - UNF:6:ANdN79QbbnM8VESWom4bZA==
Baseline and efficacy data in STATA
2SD WK48 Data Code Book_Baseline, Efficacy, Imputation and Lab AEs.xlsx
Dec 2, 2022 - Replication for Week 48 Data for Switching Treatment-Experienced, Integrase Inhibitor-Naïve, Virally Suppressed HIV-1 Infected Adults from Ritonavir boosted Protease Inhibitors to Dolutegravir: An Open-Label Randomized Controlled Trial
MS Excel Spreadsheet - 17.7 KB - MD5: 7e04571cbec7824b12295e958e27ced1
Excel code book with variable description for baseline, efficacy, imputation and lab AEs data sets
2SD WK48 Data_Descriptive Adverse Events_Grade 1 or 2 and SAEs.xlsx
Dec 2, 2022 - Replication for Week 48 Data for Switching Treatment-Experienced, Integrase Inhibitor-Naïve, Virally Suppressed HIV-1 Infected Adults from Ritonavir boosted Protease Inhibitors to Dolutegravir: An Open-Label Randomized Controlled Trial
MS Excel Spreadsheet - 32.1 KB - MD5: f179c9d91dd5e1369fbe2ce9906f61cb
Descriptive adverse events in excel
2SD WK48 Data_Lab AEs.tab
Dec 2, 2022 - Replication for Week 48 Data for Switching Treatment-Experienced, Integrase Inhibitor-Naïve, Virally Suppressed HIV-1 Infected Adults from Ritonavir boosted Protease Inhibitors to Dolutegravir: An Open-Label Randomized Controlled Trial
Tabular Data - 297.3 KB - 51 Variables, 791 Observations - UNF:6:Yq76iOs/kjJCGiZjDGi0uQ==
Lab AEs data in STATA
WK48 Dataset_VL Multiple Imputation.tab
Dec 2, 2022 - Replication for Week 48 Data for Switching Treatment-Experienced, Integrase Inhibitor-Naïve, Virally Suppressed HIV-1 Infected Adults from Ritonavir boosted Protease Inhibitors to Dolutegravir: An Open-Label Randomized Controlled Trial
Tabular Data - 41.0 KB - 12 Variables, 791 Observations - UNF:6:Zv+CyDfX8DosMw4RgeLggg==
Multiple imputation data in STATA
Revised Week 48 Data(University of Nairobi)
Dec 2, 2022
Replication for Week 48 Data for Switching Treatment-Experienced, Integrase Inhibitor-Naïve, Virally Suppressed HIV-1 Infected Adults from Ritonavir boosted Protease Inhibitors to Dolutegravir: An Open-Label Randomized Controlled Trial
Jul 13, 2022
Ombajo, Loice Achieng, 2022, "Replication for Week 48 Data for Switching Treatment-Experienced, Integrase Inhibitor-Naïve, Virally Suppressed HIV-1 Infected Adults from Ritonavir boosted Protease Inhibitors to Dolutegravir: An Open-Label Randomized Controlled Trial", https://doi.org/10.7910/DVN/NVGPHN, Harvard Dataverse, V1, UNF:6:Hnd9NmjcbBzt+bTZ1yW4+A== [fileUNF]
This is week 48 dataset from an open-label, randomized, active-controlled, multi-centre non-inferiority trial conducted by University of Nairobi. The trial enrolled 791 participants ≥ 18 years old from among people receiving outpatient HIV care at four study sites in Kenya. The variables contained in this dataset are; demographics, ARV history, bod...
2SD WK48 Codes_Baseline, Efficacy and Lab AEs.do
Jul 13, 2022 - Replication for Week 48 Data for Switching Treatment-Experienced, Integrase Inhibitor-Naïve, Virally Suppressed HIV-1 Infected Adults from Ritonavir boosted Protease Inhibitors to Dolutegravir: An Open-Label Randomized Controlled Trial
Stata Syntax - 37.1 KB - MD5: 7cb93d588e5f2db0012b95059da9673b
STATA codes for baseline and efficacy data analysis
Add Data

Sign up or log in to create a dataverse or add a dataset.

Sign Up Log In
Share Dataverse

Share this dataverse on your favorite social media networks.

Link Dataverse
Reset Modifications

Are you sure you want to reset the selected metadata fields? If you do this, any customizations (hidden, required, optional) you have done will no longer appear.